Navigation Links
Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics

intravenous), DAP (100 mg/kg subcutaneous) and CTX (50 mg/kg subcutaneous) were administered at 1 hour and 4 hours following exposure to PSSP. Results showed that ORI was more active in the mouse pneumonia model than CTX or DAP, with lungs of all mice treated with ORI presenting as sterile, while 40 percent of those that were treated with CTX and none of those treated with DAP presented with sterile lungs. In a second dose-ranging in vivo model, single doses of ORI (0.25 - 32 mg/kg intravenous) were administered one hour after exposure of mice to PSSP. This study yielded the maximum effect from dosing at 6.49 +/- 0.18 mg/kg, with a dose of 2.76 +/- 0.3 mg/kg resulting in 50 percent of the maximal killing. In Vitro The in vitro arm of the study tested the antibacterial effect of ORI, DAP and CTX against S. aureus when a pulmonary surfactant preparation (up to 5%, by volume) was added. Results showed a 2- to 4-fold increase in ORI minimal inhibitory concentration (MIC), compared with a greater than or equal to 64-fold increase for DAP MIC and no shift for CTX MIC. Researchers concluded that surfactant only minimally affected the antibacterial activity of ORI when conducted in a laboratory setting. About Oritavancin

Oritavancin, Targanta's lead product candidate, is a once-daily, semi- synthetic lipoglycopeptide antibiotic with rapid in vitro bactericidal activity against all clinically relevant serious gram-positive pathogens, including multi-resistant strains. Oritavancin's multiple targets and mechanisms of action work against the development of resistant strains, which is important when treating serious gram-positive infections. To date, over 1,500 individuals have received oritavancin in clinical trials, incl
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:9/15/2014)... 2014 The Society of Corporate Compliance ... more than 4,500 compliance and ethics professionals from ... chronicles corporate fines and settlements.  The SCALENDAR is ... a ready reference to demonstrate to employees the ... SCALENDAR to help compliance and ethics officers looking ...
(Date:9/15/2014)... Sept. 15, 2014  Over 200 patients, families, ... Saturday to learn, interact and participate in the ... first Lupus Trials Fair launched by the ... S.L.E. Lupus Foundation .  Attendees interacted directly with ... sharing experiences, ideas and needs and learning about ...
(Date:9/15/2014)... , Sept. 15, 2014 Research ... "Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014" ... (CAS 103-90-2) Market Research Report 2014 presents comprehensive data ... Europe , Asia , ... The report includes paracetamol (acetaminophen) description, covers its application ...
Breaking Medicine Technology:More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3
... PHILADELPHIA, Dec. 23, 2011 Arctic Ease is proud to ... has joined Team Arctic Ease®.  Davis will serve as a ... well as introduce Arctic Ease® to millions of sports fans ... a form of cold therapy that are odorless, menthol free ...
... 2011  Rochester Medical Corporation (Nasdaq: ROCM ) announced ... of Directors following the conclusion of the Company,s 2012 Annual ... which is the end of his current term. ... Schnobrich has served on our Board since 1995.  His cheerful ...
Cached Medicine Technology:Vernon Davis Joins Team Arctic Ease® as Spokesperson for Arctic Ease® Cryotherapy Wraps and Pads 2Vernon Davis Joins Team Arctic Ease® as Spokesperson for Arctic Ease® Cryotherapy Wraps and Pads 3Rochester Medical Director Schnobrich to Retire 2
(Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
(Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
... TUESDAY, Aug. 30 (HealthDay News) -- Genes affect hereditary coronary ... a new study. While it,s long been known that ... this is due to genes or unhealthy lifestyle in the ... that question, the investigators examined the health records of 80,214 ...
... not how old but how frail patients are that can predict ... young patients in poor health may have worse outcomes than older ... University of Michigan Comprehensive Cancer Center finds that patients with decreased ... to distant parts of the body. These findings may ...
... of Medicine researchers have found that climate change may lead ... room (ER) visits in the next decade. The data, ... Preventive Medicine, found that changing levels of ozone could lead ... by children, ages 0-17. The research team, ...
... August 30, 2011Despite recent concerns that changes in atmospheric ... insulin delivered via pump devices, the current evidence is ... more data are available, according to an insightful editorial ... journal published by Mary Ann Liebert, Inc. The editorial ...
... An Indiana University study that compared strategies used by extroverted ... happy people who are less outgoing relied less on partying ... family and friends or cognitive strategies, such as positive thinking. ... to be happy. That,s the thing students feel they need ...
... TUESDAY, Aug. 30 (HealthDay News) -- Swedish scientists have identified ... a harbinger of an increased risk of death among elderly ... the inflammatory processes that are central to killers such as ... study, published online Aug. 30 in the Journal of ...
Cached Medicine News:Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News: Happiness: All in who you know, goals 2Health News:Blood Protein Might Signal Death Risk in Elderly 2
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... Tissue Anchor 2 mm is a resorbable repair ... using sutures. The resorbable repair device is implanted ... is used to reattach damaged soft tissue. The ... derived from glycolide and lactide colored with D&C ...
... of anchor is generally used when ... This 2.9mm anchor is packaged sterile ... or 2-0) and needles. Although pre-drilling ... the Mini Harpoon®, 1.6mm & 1.8mm ...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty....
Medicine Products: